Home / News & Insights / Whistleblower Law Insights / Alpharma resolves FCA suit involving Kadian

Alpharma resolves FCA suit involving Kadian

Alpharma, a subsidiary of King Pharmaceuticals, will pay $42.5 million to resolve allegations that
it improperly marketed the morphine-based drug Kadian.

The Justice Department’s press release outlined the alleged violations: paying health care providers to promote or prescribe the drug, and making misrepresentations about its safety and efficacy.

The suit began as a whistleblower action brought under the qui tam provisions of the False Claims Act. The whistleblower, Debra Parks, was represented by Mary Louise Cohen and Tim McCormack of Phillips & Cohen LLP.

The proceeds from the settlement will be split between the federal government and various states.

Let us help you.
Get a free, confidential case review